How to Buy Opus Genetics Stock
Opus Genetics Inc
Opus Genetics, Inc. , a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
Opus Genetics stock last closed at $2.44, down 2.4% from the previous day, and has increased 103.33% in one year. It has overperformed other stocks in the Biotechnology industry by 1.5 percentage points. Opus Genetics stock is currently +275.38% from its 52-week low of $0.65, and -5.83% from its 52-week high of $2.59.
As of Dec 11, 2025, there are 68.96M shares of IRD outstanding. The market capitalization of IRD is $168.27M. In the last 24 hours, 348,000 IRD shares were traded.
How to Buy Opus Genetics Stock
Wondering how to invest in Opus Genetics stock? Here's how.
- Choose where to buy Opus Genetics stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you figure out where to buy Opus Genetics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Pick your payment method and add your details.
- Research Opus Genetics stock: The Opus Genetics ticker symbol is IRD. Is Opus Genetics stock a good investment? Should you buy shares of IRD? How do IRD's underlying business fundamentals look? Do top analysts think Opus Genetics is a good buy? Why has IRD's stock price moved recently? (Hint: Our stock analysis website can help you decide if IRD is a good stock to buy).
- Place your IRD buy order: Decide if you will purchase IRD shares at the current market price or use a limit order to purchase IRD stock at a given price.
- Get the latest news on your IRD investment: Create a watchlist to monitor your position in Opus Genetics stock.
Step 1: Choose where to buy Opus Genetics stock
You will need an online brokerage account in order to access the NASDAQ market and buy IRD stock.
Our recommended brokerage: eToro
We believe that eToro is the best online stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the best brokerage, it's time to fill out some personal information so you can invest in IRD today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create your new trading account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have opened your account on one of the most highly reviewed stock apps, you can securely and quickly fund your account:
Watch this video walkthrough if you need help transferring funds into your new investment account.
Step 4: Research Opus Genetics stock
After you have identified the best place to buy Opus Genetics stock, it's critical to evaluate their stock before you buy, so you actually understand the risk as well as the opportunity.
Opus Genetics stock quick numbers
Opus Genetics Fundamentals
WallStreetZen was designed to help average investors do better fundamental analysis in less time.
You can see all of the due diligence checks on IRD's stock page.
Is IRD stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge IRD's fair value.
Using relative valuations ratios:
- IRD could be overvalued based on its P/B ratio of 28.2x, relative to Biotechnology industry P/B ratio of 5.34x
You can do more valuation research on IRD's stock here.
IRD Financial Health
Pros:
- There are more short-term assets than long-term liabilities on the IRD balance sheet.
- There are more short-term assets than short-term liabilities on the IRD balance sheet.
Cons:
- IRD profit margin has gone down from -324.4% to -466.1% in the past year.
- IRD has cash burn of 32858000. It does not have sufficient cash and short-term investments to cover this.
- IRD has a relatively high debt to equity ratio of 5.05.
- Total IRD debt is higher than 5 years ago, relative to shareholder equity.
- IRD has $30.82M in cash and short term investments. This is not sufficient to cover its annual cash burn of $32.86M.
Do analysts think it's a good time to buy Opus Genetics stock
Out of 6 Equities analysts who give forecasts on IRD, the consensus analyst rating on IRD is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest IRD Analyst Ratings
Dev Prasad, a top 35% analyst from LUCID CAPITAL MARKETS initiates coverage on IRD with a strong buy rating and announces their IRD price target of $5.00, on Jun 17, 2025.
You can dig deeper into what analysts are projecting on the Opus Genetics stock forecast page.
IRD Technicals
IRD Earnings
Last year, IRD revenue was $14.63M. In the last 4 year, IRD's revenue has grown by 123.26% per year. This was faster than the Biotechnology industry average of 43.95%.
Find out more about IRD's earnings and revenue performance here.
Are IRD executives and large shareholders buying or selling the stock?
In the last year, executives and large shareholders at IRD have sold more shares than they have bought.
Foundation Fighting Blindness Retinal Degeneration Fund, Director of IRD, was the latest IRD insider to sell. They sold $8,600,000.00 worth of IRD shares on Dec 9, 2025.
Dig into more about who owns IRD stock here.
Can I rely on IRD as an income stream?
No, Opus Genetics doesn't provide an income stream by paying out dividends.
IRD Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your IRD buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a specific dollar amount limit, place a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more help with buying stocks on eToro, watch the helpful video below:
Step 6: Get the latest news on your IRD investment
Now that you own some IRD stock, you'll want to stay up-to-date on your investment.
Add IRD to a watchlist to get notified of important updates regarding your IRD stock.
IRD Feed
How to Buy Stock in Opus Genetics
To reiterate, here are the 6 steps for buying Opus Genetics stock:
- Choose where to buy Opus Genetics stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Research Opus Genetics stock
- Place your IRD buy order
- Get the latest news on your IRD investment
If you are looking for a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your investment in Opus Genetics, create your watchlist below.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.